GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
GENELUX Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.45+0.03 (+1.24%)
Close on Oct 19, 2026
- Market cap
- $110.15M
- P/E (TTM)
- –
- Dividend yield
- –
Genelux statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Genelux | Industry median |
|---|---|---|
| Market Cap | $110.85M | $166.30M |
| Enterprise Value | $92.17M | $88.19M |
| PB Ratio | 6.88 | 2.03 |
| P/TBV Ratio | 6.88 | 2.29 |
Income (trailing twelve months)
| Measure | Genelux | Industry median |
|---|---|---|
| Operating Income | -$36.42M | -$21.40M |
| Net Income | -$35.60M | -$22.46M |
| EBITDA | -$36.42M | -$16.91M |
| EPS (Diluted) | -$0.86 | -$0.83 |
Returns
| Measure | Genelux | Industry median |
|---|---|---|
| Return on Equity (ROE) | -177.9% | -53.2% |
| Return on Assets (ROA) | -121.8% | -40.9% |
| Return on Capital Employed (ROCE) | -200.0% | -38.1% |
Growth
| Measure | Genelux | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -91.0% | 2.25% |
Balance sheet
| Measure | Genelux | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $18.68M | $61.43M |
| Net Cash (Debt) | $18.68M | $15.35M |
| Net Cash Per Share | $0.41 | $0.66 |
| Equity (Book Value) | $16.11M | $49.09M |
| Book Value Per Share | $0.36 | $1.37 |
| Tangible Book Value | $16.11M | $23.52M |
| Working Capital | $11.15M | $76.81M |
Financial position
| Measure | Genelux | Industry median |
|---|---|---|
| Current Ratio | 2.39 | 3.34 |
| Quick Ratio | 2.34 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Genelux | Industry median |
|---|---|---|
| Operating Cash Flow | -$25.28M | -$12.35M |
| Capital Expenditures | -$3.41M | -$1.08M |
| Free Cash Flow | -$28.68M | -$20.22M |
| FCF Per Share | -$0.63 | -$0.42 |
Dividends and yields
| Measure | Genelux | Industry median |
|---|---|---|
| Earnings Yield | -32.1% | -23.3% |
| FCF Yield | -25.9% | -8.72% |
| Buyback Yield | -17.0% | -0.59% |
| Shareholder Yield | -17.0% | 0.00% |
Shares
| Measure | Genelux | Industry median |
|---|---|---|
| Shares Outstanding | 45,245,300 | 58,127,000 |
| Shares Change (YoY) | 16.3% | 10.9% |
| Shares Change (QoQ) | 0.59% | 0.54% |
| Float | 41,739,400 | 49,136,700 |
| Shares Held by Insiders | 7.75% | 11.6% |
| Shares Held by Institutions | 21.7% | 59.4% |
Scores
| Measure | Genelux | Industry median |
|---|---|---|
| Altman Z-Score | -13.62 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Genelux's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.